Tech start-up Sensory Cloud has acquired an exclusive worldwide license for Pulmatrix salt formulations PUR 003 and PUR 006 (NasoCalm), for purposes of “OTC nasal delivery to potentially reduce the pathogenic risk and transmissibility of contagions, including with respect to COVID-19.” Sensory Cloud will pay royalties rising from 7% this year to 14% in 2021 and 17% thereafter; Pulmatrix will also receive a $1 million milestone payment if Sensory Cloud achieves aggregate net sales of $20 million on the licensed products.
Sensory Cloud CEO David Edwards, who was one of the founders of Pulmatrix, said, “As the COVID-19 pandemic continues to evolve, there is an urgent need for practical, easy to administer and widely available interventions to prevent the spread of disease. We are encouraged by the data for Pulmatrix’s NasoCalm, and believe Sensory Cloud’s unique platform for personal olfaction will provide an effective, affordable and fast-to-market way for bringing NasoCalm to healthcare workers and others on the front lines as we battle this unprecedented challenge. Importantly, NasoCalm’s demonstrated safety should enable future over-the-counter options to the broader population, with potential to mitigate the effects of this devastating pandemic.”
Pulmatrix CEO Ted Raad commented, “Pulmatrix roots were as a biodefense company and we were eager to leverage our experience and NasoCalm to help combat the rapidly emerging COVID-19 global pandemic. Years ago we developed NasoCalm as a potential anti-infective biodefense medical countermeasure product. With results that show reduced viral progression and contagion in animal models, and demonstrated reductions of contagious bioaerosols and safety in humans, we believe NasoCalm may be a tool to manage the spread of COVID-19. We look forward to partnering with Dr. Edwards and Sensory Cloud to seek rapid delivery of an Emergency Response Product to those most at risk of infection.”
Over the past several months, Pulmatrix has also announced deals with the Lung Cancer Initiative at Johnson & Johnson for narrow spectrum kinase inhibitors formulated using Pulmatrix’s iSPERSE technology and with Nocion Therapeutics for use of iSPERSE technology for formulation of Nocion drugs.
Read the Pulmatrix press release.
